Part A. The Reasons for Failure1. The Medical R&D Fiasco2.
Academia Is Marching to the Wrong Drummer3. Mavericks Versus the
Establishment4. The Strangled Unincentivized Drug Industry5. The
FDA Roadblock to Cures6. The Liability Barrier
Part B. Towards Solutions7. Cleaning Up the Academic Research
Quagmire8. Reforming the FDA9. Enabling the Drug Industry10. Patent
and Liability Reform11. The Public Will Make It Happen
A detailed expose of terminal disease research design and how it can be improved to further the search for cures.
Dr. Marangos is author of 252 peer-reviewed research papers on
neurobiology, and 4 books – three by Academic Press (the
Neurobiological Research series of volumes) and a fourth titled
“Emerging Strategies in Neuroprotection. He is a founding editor
of “The Journal of Molecular Neuroscience and inventor on 14
issued patents. He spent 13 years at the NIMH and was adjunct
professor of neurochemistry at GW School of Medicine during that
time. He is co-Founder of five Biotech firms with over 20 years of
experience as CEO of both public and private life science
companies. He has had extensive experience in all aspects of the
pharmaceutical and biotechnology industries from bench to product.
This coupled with his academic experience has provided a global
perspective on the entire medical R&D enterprise, in particular
its faults, and remedies to speed the quest for cures.
https://www.wsj.com/articles/the-terminally-ill-need-more-than-the-right-to-try-1534200199?mod=searchresults&page=1&pos=1
https://www.prnewswire.com/news-releases/biomedica-partners-proposes-the-terminal-disease-act-300609691.html?tc=eml_cleartime
http://thehill.com/opinion/healthcare/383484-right-to-try-efforts-have-have-been-timid-and-poorly-conceived
https://www.prnewswire.com/news-releases/biomedica-partners-presents-major-reforms-in-terminal-disease-drug-development-at-magis-clinical-research-conference-300642731.html
|
Ask a Question About this Product More... |
|
